|
|
News Breaks | | | | November 13, 2012 | | 13:05 EDT |  | ABT | Abbott says over 2,000 patients to be included in phase 3 program for HCV
Abbott released details on its phase 3 hepatitis C registrational program following results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease in Boston. Topline intent-to-treat results from the 12-week, triple-DAA regimens with ribavirin presented at the AASLD meeting this week found that 97.5%, or 77 of 79, of treatment-naïve GT1 patients and 93.3%, or 42 of 45, in GT1 null responder patients achieved SVR12. The phase 3 clinical trials are designed to evaluate safety and efficacy of a 12-week regimen of three direct acting antivirals, with and without ribavirin, for the treatment of HCV in genotype 1 non-cirrhotic, treatment-naïve and treatment-experienced patients. An additional phase 3 trial will study triple-DAAs, with ribavirin, in patients with cirrhosis for 12 or 24 weeks. The phase 3 program, which is currently open for enrollment, will include more than 2,000 patients with HCV genotype 1, with trial sites in 29 countries. The DAAs in the studies include ABT-450/r, ABT-267 and ABT-333. Treatment duration will be 12 weeks in non-cirrhotic patients, and 12 or 24 weeks in cirrhotic patients. All patients will be followed for 48 weeks post-treatment. Co-formulated tablets of ABT-450/r and ABT-267 will be used in the phase 3 trials, the company said. | |
|
News For ABT From The Last 14 Days Check below for free stories on ABT the last two weeks. |
|
|
| June 19, 2013 | | 08:45 EDT |  | ABT | Leerink's biotech analyst holds analyst/industry conference call on ADA
Analyst Antlaffy, along with Dr. George Grunberger, founder & Chairman of the Grunberger Diabetes Institute, preview the upcoming American Diabetes Association's conference, including perspectives on new devices in diabetes, potential disruptive technologies at ADA and progress towards the artificial pancreas on an Analyst/Industry conference call to be held on June 20 at 2 pm. | | | June 18, 2013 | | 07:28 EDT | | ABT | Wells Faro to host a conference
 Subscribe for More Information | | | June 14, 2013 | | 12:23 EDT | | ABT | Abbott announces new $3B share repurchase plan
Subscribe for More Information | | | 12:23 EDT | | ABT | Abbott announces new $3B share repurchase plan
| | | June 13, 2013 | | 11:02 EDT | | ABT | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information | | | June 11, 2013 | | 09:33 EDT | | ABT | Abbott begins Absorb BVS clinical trial in Japan
Subscribe for More Information | | | June 6, 2013 | | 08:03 EDT |  | ABT | Abbott shares compelling, says Wells Fargo
Subscribe for More Information | |
|
|
|
|
|
|
